Correlation of Glycated Hemoglobin (HbA1c) with Different Cardiovascular Risk Factors in Non-diabetic Patients

Abdul Ghaffar Memon, Muhammad Khan Soomro and Mubashir Ali Kolachi

Department of Cardiology, Liaquat University of Medical and Health Sciences Jamshoro/Hyderabad, Pakistan

Keywords: HbA1c; CVD; Non diabetic

Introduction

Hemoglobin glycation, found via percent HbA1c, was initially practiced clinically before 30 years to review chronic hyperglycemia degree in diabetic cases in those whose values reveal weighted average levels of glucose above former 3-months [1]. Over bygone three decades, prominent HbA1c is determinedly connected to risk of long-term complications of micro vessels and HbA1c evaluation is currently used far and wide to monitor proficient glycemic control as diabetes care cornerstone. With presentation of reference technique consistency, issues concerning high inter-assay as well as inter-laboratory analytic inconsistency have been greatly overwhelmed such that during 2002, 98% of United States laboratories surveyed practiced consistent techniques [2]. Given these positive performance uniqueness, current analytical efforts have endeavored to extend the HbA1c part as an increasing glycaemic exposure index in cardiovascular risk and diabetes valuation in non-diabetic cases. Numerous studies have assessed HbA1c levels ability to forecast prospect type 2 diabetes among pre-diabetic, high-risk patients [3,4] and up to date data propose that HbA1c can possibly as well be handy in the detection of diabetes valuation in non-diabetic cases. Numerous studies have assessed HbA1c levels ability to forecast prospect type 2 diabetes among pre-diabetic, high-risk patients [3,4] and up to date data propose that HbA1c can possibly as well be handy in the detection of diabetes valuation in non-diabetic cases. Numerous studies have assessed HbA1c levels ability to forecast prospect type 2 diabetes among pre-diabetic, high-risk patients [3,4] and up to date data propose that HbA1c can possibly as well be handy in the detection of cardiovascular events [5,6]. Significantly, whether an only HbA1c assessment can be applied in this purpose, stays uncertain and future population-established studies of the cases at low to moderate risk are exceptional. In a former periodical case-control investigation [7], we established that a high level of HbA1c was a univariated predictor of incidental cardiovascular events, however this influence was not considerable subsequent to adjustment for rest of the risk factors cardiovascular disease. Though, we did not scrutinize non-linear threshold consequences that can possibly have prognostic importance as was demonstrated in several future studies of incident cardiovascular and plasma glucose events [8,9] and as a minimum one finding of cardiovascular mortality and HbA1c. Hence our purpose to evaluate the levels of HbA1c correlation with cardiovascular events in non-diabetic patients.

Methodology

This prospective study was performed at cardiology department of Liaquat University of medical and health science. Total 130 cases were selected in this study. All the cases were selected with different cardiovascular diseases and having age more than 40 years. Each subject experienced a complete physical assessment, and a self-administered survey presented data concerning medical history, drinking habits and smoking, physical activity of free time, medication and healthcare system contact history. BP was calculated through electronic sphygmomanometer. Cholesterol and plasma glucose levels were calculated in venous blood samples while non-fasting. ECG was documented at rest during supine pose, and results were delineated. Hba1c measurement for haemolysed entire blood collection was done at the initial visit. All the cases those having multiple risk factors of cardiovascular disease were excluded from the study. HbA1c blood test was send to the diagnostic research lab of Liaquat University of Medical and health science. HbA1c was recorded in the proforma according to risk factors. All the data regarding HbA1c level and its related cardiovascular risk were entered in the proforma.

Abstract

Objective: To determine the HbA1c levels correlation with cardiovascular events among non-diabetic patients.

Material and methods: The prospective study was conducted at cardiology department of Liaquat University of medical and health science. Total 130 cases were selected in this study. All the cases were selected with different cardiovascular diseases and having age more than 40 years. All the cases having multiple risk factors of cardiovascular disease were excluded from the study. HbA1c blood test was send to the diagnostic research lab of Liaquat University of Medical and health science. HbA1c was recorded in the proforma according to risk factors. All the data regarding HbA1c level and its related cardiovascular risk were entered in the proforma.

Results: Mean age of the patients was found as Mean+SD=42.4±5.43 years. While majority of the cases 45 (42.6%) were found with age group of 51–60 years. Male were found in the majority 64% and female were found 36% in the cases. According to the cardiovascular risk factors smoking was found most common in 30.76% of the cases, 2nd most common risk factors were found hypertension and dyslipidemia, with percentage of 25.38% and 23.07% respectively. In this series HbA1c associated with hypertension, obesity and dyslipidemia.

Conclusion: We have found that HbA1c level is highly correlated with risk factors of CVD, especially in obesity, hypertension and dyslipidemia amongst individuals without DM.
Results

Mean age of the patients was found as Mean+SD=42.4±5.43 years. While majority of the cases 45 (42.6%) were found with age group of 51–60 years, following by 40–50 years, 61–70 years and >70 years with the percentage of 40 (26.0%), 30 (20.0%) and 15 (5.3%) patients respectively (Table 1).

| Gender          | Frequency (%) |
|-----------------|---------------|
| Mean + SD       | 42.4±5.43     |
| Age groups      |               |
| 40-50           | 40 (26.0%)    |
| 51-60           | 45 (42.6%)    |
| 61-70           | 30 (20.0%)    |
| >70             | 15 (5.3%)     |

Table 1: Age distribution N=130.

Male were found in the majority 64% and female were found 36% in the cases (Figure 1).

In this series HbA1c associated with hypertension, obesity and dyslipidemia (Table 3).

Table 2: CVD risk factors distribution N=130

| CVD Risk Factors     | Frequency | %   |
|----------------------|-----------|-----|
| Hypertensive         | 33        | 25.38% |
| Obesity              | 15        | 11.53% |
| Smoking              | 40        | 30.76% |
| Alcohol consumption  | 12        | 9.23%  |
| Family history       | 10        | 7.69%  |
| Dyslipidemia         | 30        | 23.07% |

Table 3: HbA1c distribution according to CVD risk factors N=130.

Discussion

In this study, we found that HbA1c is associated with CVD development among non-diabetic cases. Thus, cases with no DM with levels of HbA1c in normal range of reference had an escalated risk of CVD development. In this finding patients’ mean age was found as Mean+SD=42.4±5.43 years. While majority of the cases 45 (42.6%) were found with age group of 51–60 years. O’Sullivan et al. [10] reported that 72 years was the mean age and 59% were men. This study found that HbA1c is associated with hypertension and dyslipidemia, with percentage of 25.38% and 23.07% respectively. A finding on disease of coronary artery, exhibited that the overall 42% cases were hypertensive [12]. During the study of Arvind kumar et al., observed elevated smoking rates as a risk factor and as well as men in majority were involved [13]. In Masood et al. finding, 1186 (53.8%) cases were hypertensive, sixty six (41.3%) were smokers, fifty eight (36.3%) retained diabetes mellitus, thirty eight (23.8%) cases retained family ischemic cardiac disease history and forty (25%) cases retained dyslipidemia. In this series HbA1c associated with hypertension, obesity and dyslipidemia. Raised risk of CVD was observed in three uppermost HbA1c quartiles. In the uppermost quartile, risk was obvious following HbA1c levels and the development of DM. In current study, we exhibit that HbA1c is related to CVD risk within our populace. Preceding studies investigating HbA1c role as a DM predictor have conventionally been carried out in high-risk [14-16] heterogeneous or small populaces [17,18]. In current study, we observed an obvious association in future CVD risk and HbA1c levels in common population. Our outcomes did not widen to discovery of statistically considerable relations in incident CVD events and HbA1c. Moreover, macro vascular complications development was not associated to levels of HbA1c in these matters. This is contrary to the outcomes of prior epidemiological cohort findings, which though in short of standardized HbA1c measurements and risk factors adjustment. However, interventional findings have exhibited slight or a probable harmful outcome of reducing HbA1c to avoid CVD events in cases which are non-diabetic [17,18] emphasize that either the association between DM and CVD (as well as arterial disease) is causal or not, remains mysterious and certainly that HbA1c can possibly be distal to genuine pathological outcomes related to cardiovascular
Among nondiabetic cases, the part of HbA1c is uncertain. Selvin et al. [19] mentioned a relationship in CVD and HbA1c in a community-based finding of nondiabetic individuals in heterogeneous population of America. Other authors reported alike outcomes, though inconsistently [20,21].

**Conclusion**

In the given study, we established that level of HbA1c is greatly associated to the CVD development amongst case without DM, especially in the cases having obesity, dyslipidemia and old age. More studies with big sample size are required for further confirmation.

**References**

1. Tahara Y, Shima K (1995) Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 18: 440-447.
2. Little RR (2003) Glycated hemoglobin standardization-National Glycohemoglobin Standardization Program (NGSP) perspective. Clin Chem Lab Med 41: 1191-1198.
3. Little RR, England JD, Wedemeyer HM, Madsen RW, Pettitt DJ, et al. (1994) Glycated haemoglobin predicts progression to diabetes mellitus in Pima Indians with impaired glucose tolerance. Diabetologia 37: 252-256.
4. Ko GT, Chan JC, Tsang LW, Cockram CS (2000) Combined use of fasting plasma glucose and HbA1c predicts the progression to diabetes in Chinese subjects. Diabetes Care 23: 1770-1773.
5. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, et al. (2001) Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 322: 15-18.
6. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, et al. (2004) Association of glycated A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141: 413-420.
7. Blake GJ, Pradhan AD, Manson JE, Williams GR, Buring J, et al. (2004) Hemoglobin A1c level and future cardiovascular events among women. Arch Intern Med 164: 757-761.
8. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, et al. (1998) High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21: 360-367.
9. Scheidt-Nave C, Barrett-Connor E, Wingard DL, Cohn BA, Edelstein SL (1991) Sex differences in fasting glycemia as a risk factor for ischemic heart disease death. Am J Epidemiol 133: 565-576.
10. O’Sullivan CJ, Hynes N, Mahendran B, Andrews EJ, Avalos G, et al. (2006) Haemoglobin A1c (HbA1C) in non-diabetic and diabetic vascular patients. Is HbA1C an independent risk factor and predictor of adverse outcome? Eur J Vasc Endovasc Surg 32: 188-197.
11. Massoud A, Ali Naqi M, Sohail S (2009) In-hospital outcome of acute myocardial infarction in correlation with thrombolysis in myocardial infarction risk score. J Ayub Med Coll Abbottabad 21.
12. Gupta R, Prakash H, Majumdar S, Sharma S, Gupta VP (1995) Prevalence of coronary heart disease and coronary risk factors in an urban population of Rajasthan. Indian Heart J 47: 331-338.
13. Kumar A, Garg S, Gupta HL (2005) A Study of Prevalence of Risk Factors for Coronary Artery Diseases in Asymptomatic Middle Aged and Elderly Subjects. Hypertension 14: 17.
14. Narayan KM, Hanson RL, Pettitt DJ, Bennett PH, Knowler WC (1996) A two-step strategy for identification of high-risk subjects for a clinical trial of prevention of NIDDM. Diabetes Care 19: 972-978.
15. van’t Riet E, Rijkelijkhuizen JM, Alssema M, Nijpels G, Stehouwer CD, et al. (2012) HbA1c is an independent predictor of non-fatal cardiovascular disease in a Caucasian population without diabetes: a 10-year follow-up of the Hoorn Study. European Journal of Preventive Cardiology 19: 23-31.
16. Bonora E, Kiechl S, Mayr A, Zoppini G, Targher G, et al. (2011) High-normal HbA1c is a strong predictor of type 2 diabetes in the general population. Diabetes Care 34: 1038-1040.
17. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, et al. (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-2559.
18. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
19. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, et al. (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362: 800-811.
20. Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S (1996) GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes: the Rancho Bernardo Study. Diabetes Care 19: 450-456.
21. Lawlor DA, Fraser A, Ebrahim S, Smith GD (2007) Independent associations of fasting insulin, glucose, and glycated haemoglobin with stroke and coronary heart disease in older women. PLoS Med 4: e263.